Fuzeon (Enfuvirtide, T-20)
Fuzeon (enfuvirtide, T-20) is the first in a new class of anti-HIV meds called fusion inhibitors (also known as entry inhibitors). Fusion inhibitors fight HIV in a completely different way than existing anti-HIV drugs. Read More >>
- I Am Resistant to Most Meds and Want to Know What My Options Are. Could Fuzeon Be Right for Me?
- Why Is Fuzeon Used by HIVers With Resistance to Other Meds?
- Can I Make Three Vials of Fuzeon at Once?
- Is There Some Sort of Systemic Reaction to Long-Term Fuzeon Use?
- Fuzeon Improves Isentress Response by Approximately 20%
In a study of the new integrase inhibitor Isentress in heavily treatment-experienced, HIV-infected patients, 70% to 73% of them achieved viral loads below 400 copies/mL by 24 weeks when taking Isentress plus an optimized background regimen. These are remarkable results for a drug that appears to not only be extremely well tolerated, but also has minimal drug interactions. The use of Fuzeon improved the Isentress response by an approximate 20% in all groups studied. Edwin DeJesus, M.D., reports. Read More >>
 | ||||
 |  |  | ||
| Greg Braxton | Louise Perry | Don Kurtyka, A.R.N.P. | ||
| Got questions about Fuzeon? See what others have asked at The Body's chat with Greg Braxton and Louise Perry. Click here for a transcript of a chat with Don Kurtyka and Rob. | ||||
 | ||
| Brand Name: |
Fuzeon |
|
| Generic Name: |
Enfuvirtide, T-20 |
|
| Adult Single Dose: |
Patients weighing more than 94 lbs (42.6 kg): 90 mg (1 mL) injected subcutaneously into the upper arm, thigh, or abdomen (twice a day) |
|
| Food & Liquid Restrictions: |
None |
|
| Drug Class: |
Fusion inhibitor |
|
| Patient Information About Fuzeon >> | ||
 |
A Guide to Fuzeon |
| This easy-to-read guide from The Body will tell you all you'll need to know about Fuzeon. Click here to browse. | |